Sign In
Buy ACRX
$0.86
+0 (+0%)
At Close: Apr 08, 2024
SHAREHOLDER ALERT: Robbins LLP Announces that AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders
12:13pm, Monday, 14'th Jun 2021
SAN DIEGO & HAYWARD, Calif.--(BUSINESS WIRE)---- $ACRX #ACRX--Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of all purchasers of AcelRx Therapeutics, I
LOS ANGELES--(BUSINESS WIRE)---- $ACRX #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on be
New York, New York--(Newsfile Corp. - June 12, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX
NEW YORK, June 11, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AcelRx Pharm
LOS ANGELES--(BUSINESS WIRE)---- $ACRX #ACRX--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc.
BENSALEM, Pa.--(BUSINESS WIRE)---- $ACRX #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased AcelRx Pharmaceuticals,
LOS ANGELES--(BUSINESS WIRE)---- $ACRX #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on
NEW YORK, June 10, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. (
The Law Offices of Frank R. Cruz Announces Investigation of AcelRx Pharmaceuticals, Inc. (ACRX) on Behalf of Investors
05:00pm, Wednesday, 09'th Jun 2021
LOS ANGELES--(BUSINESS WIRE)---- $ACRX #investors--The Law Offices of Frank R. Cruz Announces Investigation of AcelRx Pharmaceuticals, Inc. (ACRX) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)---- $ACRX #ACRX--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AcelRx Pharmaceuticals, Inc. (ACRX) on Behalf of Investors
02:56pm, Wednesday, 09'th Jun 2021
BENSALEM, Pa.--(BUSINESS WIRE)---- $ACRX #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of AcelRx Pharmaceuticals, Inc. (“AcelRx” or the “Company”) (NASDAQ:
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AcelRx Pharmaceuticals, I
NEW YORK--(BUSINESS WIRE)-- #AcelRX--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States Distric
Pomerantz Law Firm Announces the Filing of a Class Action Against AcelRx Pharmaceuticals, Inc. and Certain Officers - ACRX
05:25pm, Tuesday, 08'th Jun 2021
NEW YORK, June 8, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain o
HAYWARD, Calif., June 1, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative
